entertainment -WSS

entertainment

author：Wikipedia 2025-10-02 13:40:55 - browse：77

Scientist walks up a strand of DNA -- First Opinion coverage from STAT — Adobe

Eli Lilly said Tuesday that it will pay $200 million to gene-editing firm Beam Therapeutics for Beam’s stake in Verve Therapeutics, another gene-editing company focused on treatments for heart disease.

The deal, which also includes future milestone payments, is evidence that despite the pressure on biotechnology stocks there is still interest in very early cutting-edge technologies among big pharmaceutical players. It also provides Beam, which announced on Oct. 19 that it would cut 100 jobs, or 20% of its workforce, to save cash, a large infusion of money.

“This is like a true win-win-win deal, which is rare in this business, but it’s really, really exciting to see,” said John Evans, Beam’s CEO, in an interview with STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

WSS

Weight loss drugs should be covered by insurers, AMA says

Using force crossed my mind when examining a defiant young patient

Healthy food access boosts outcomes in two studies

Childhood vaccination ad campaign launches in the U.K.

A letter from the executive editor: STAT UnitedHealth investigation

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

hotspot

entertainment

knowledge

Wildfire smoke exposes gaps in outdoor worker protections

Cholera vaccine supplies dangerously low, outbreaks surging

Bright Health sells Medicare Advantage business to Molina

CDC advisory group OKs chikungunya vaccine

Alkermes shareholders re

Doctor of U.S. President Joe Biden says he is fit for duty

Medical records are filled with copy

White House drug czar issues call for 'recovery

State Dept. review finds Biden bears some blame for Afghanistan failures

First transplant of an entire human eye performed

knowledge

Type 2 diabetes prevention programs work at large scale: study

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Medicare Advantage isn’t working — for anyone

Cholera vaccine supplies dangerously low, outbreaks surging

CVS, Rite Aid closures threaten to worsen pharmacy deserts

CVS, Rite Aid closures threaten to worsen pharmacy deserts

leisure time

leisure time

explore

focus